Pluristem's PLX Cell Therapy Considered for Accelerated Development
The company is in discussions with Europe’s Adaptive Pathways Group on clinical trials that would evaluate its PLX cells for the treatment of specific diseases.
Pluristem Therapeutics, Inc. has been in detailed discussions with Europe’s Adaptive Pathways Discussion Group regarding the clinical development of its placenta-based cell therapy products (PLX cells) for treatment of critical limb ischemia (CLI) and other illnesses.
The company has received guidance on design for initial Phase II trials in a subgroup of patients with severe CLI. If results from this trial are positive, Pluristem could receive conditional approval to commercialize the cells for this treatment, accelerating the move from lab to market.
European regulators are offering this guidance because PLX cells were selected for study by the European Medicine Agency's Adaptive Pathways project back in May 2015.
Pluristem also discussed potential Adaptive Pathways development for PLX cells in treatment of ischemic stroke, muscle wasting, hip fracture, and additional subgroups of CLI.
Adaptive Pathways is part of a European Medicine Agency's (EMA) program to speed up and improve access to new therapies that target unmet medical needs. The goal is to reduce the time to a medicine's approval or to its reimbursement for targeted patient groups.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
